Inhibition of NF-κB and Akt pathways by an antibody-avidin fusion protein sensitizes malignant B-cells to cisplatin-induced apoptosis

ERIKO SUZUKI1*, TRACY R. DANIELS3*, GUSTAVO HELGUERA3, MANUEL L. PENICHET3,4, KAZUO UMEZAWA2 and BENJAMIN BONAVIDA4

1Department of Urology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 165-8582; 2Department of Applied Chemistry, Keio University, 3-14-1 Hiyoshi, Kohoku-ku, Yokohama 223-0061, Japan; Departments of 3Surgery, Division of Surgical Oncology, 4Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, The Molecular Biology Institute, Jonsson Comprehensive Cancer Center, University of California at Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA

Received January 4, 2010; Accepted February 1, 2010

DOI: 10.3892/ijo_00000615

Abstract. Multiple myeloma (MM) is an incurable disease of malignant plasma cells. Recent therapeutic advancements have resulted in improved response rates, however, there is no improvement in overall survival, therefore, new therapeutics are needed. Since the transferrin receptor is upregulated on the surface of MM cells, we previously developed an antibody fusion protein consisting of an IgG3 specific for the human transferrin receptor 1 (TfR1, CD71) genetically fused to avidin at its carboxy-terminus (ch128.1Av). We have previously shown that ch128.1Av exhibits intrinsic cytotoxicity against certain malignant B-cells by disrupting the cycling of the TfR and decreasing TfR cell surface expression resulting in lethal iron starvation. In addition, ch128.1Av can sensitize malignant cells to apoptosis induced by gambogic acid, a herbal drug used in Chinese medicine. In this study, we hypothesized that ch128.1Av may also sensitize drug-resistant malignant B-cells to chemotherapeutic agents by inhibiting key survival pathways. In this study we show that ch128.1Av sensitizes malignant B-cells to apoptosis induced by cisplatin (CDDP). The sensitization by ch128.1Av resulted in the inhibition of the constitutively activated Akt and NF-κB survival/antiapoptotic pathways and downstream decreased expression of anti-apoptotic gene products such as BclxL and survivin. The direct role of the inhibition of the Akt and NF-κB pathways by ch128.1Av in CDDP-mediated cytotoxicity was demonstrated by the use of specific chemical inhibitors and siRNA which mimicked the effects of ch128.1Av. Overall, this study provides evidence of the therapeutic potential of ch128.1Av as a chemo-sensitizing agent in drug-resistant tumor cells.

Introduction

Increasing knowledge of the biology of multiple myeloma (MM) is already contributing to the design of new drugs that target cellular proteins or pathways involved in the pathophysiology of this disease. These agents include inhibitors of tyrosine-kinase receptors (TKR) (1), agents acting through cell-surface receptors such as monoclonal antibodies against plasma-cell antigens (2), and inhibitors of signaling pathways such as NF-κB inhibitors (3-5) and Akt inhibitors (6,7). Patients with MM are treated with chemotherapy and recently with the proteasome inhibitor Bortezomib (8). However, there are patients who either do not respond to such treatments or develop resistance. Therefore, novel therapeutic approaches are needed as alternative strategies to treat this disease.

Transferrin primarily functions as an iron transporter through the blood. The transferrin receptor 1 (TfR1, CD71) is ubiquitously expressed on normal cells at various levels (9). TfR1 expression is increased in cells with a high proliferation rate or on cells that require large amounts of iron. In normal tissues, the constitutive expression of the TfR1 is limited to the liver, epidermis, intestinal epithelium, vascular endothelium of brain capillaries, and certain populations of blood cells in the bone marrow (9). In contrast, high levels of TfR1 expression have been identified in many tumors including MM (9). Due to its pivotal role in iron uptake, TfR1 is expressed more abundantly in malignant cells compared to normal cells and in many cases, this increased expression correlates with tumor stage and poor prognosis (9,10). Due to its extracellular accessibility and its upregulation on the surface of malignant cells, the TfR1 has been widely used for the delivery of many therapeutics into cancer cells by receptor-mediated endocytosis (11).
In order to target the TIR1, we previously generated a mouse/human chimeric antibody fusion protein specific for TIR1 (12-14). This fusion protein (ch128.1Av) contains the variable regions of the murine antibody 128.1 and human IgG3 constant regions that are genetically fused to avidin at the carboxy-terminus of the heavy chains. This molecule was originally designed as a delivery vehicle with the ability to deliver many biotinylated anti-tumor compounds into cancer cells. We have previously shown that ch128.1 delivers active biotinylated molecules into cancer cells, including saporin, a toxin derived from the plant *Saponaria officinalis* (12,15). We have also shown that ch128.1Av exhibits intrinsic cytotoxic activity alone against certain malignant B-cells (13,16). This cytotoxicity is due to a disruption of the constitutive TIR1 cycling pathway that leads to decreased TIR1 surface expression and ultimately, at least after 48 h, lethal through iron deprivation (13). More recently, we have demonstrated that ch128.1Av enhances the cytotoxicity of gambogic acid, a traditional Chinese medicine that can also bind the TIR1 (16). The antibody fusion protein can also sensitize malignant B-cells to gambogic acid-induced apoptosis (16).

In the current study, we hypothesized that ch128.1Av may also sensitize malignant B-cells to more traditional chemotherapeutic drugs. This hypothesis was tested and the following were investigated: a) Does the combination treatment of ch128.1Av and the chemotherapeutic drug cis-diaminedichloroplatinum (II) (CDDP, also known as cisplatin) result in enhanced cytotoxic effects? b) Does ch128.1Av-mediated sensitization result from inhibition of constitutively activated cell survival/anti-apoptotic pathways such as the NF-κB and Akt pathways? c) Does inhibition of NF-κB activity by ch128.1Av mediate, in part, CDDP-induced sensitization to apoptosis? Does the NF-κB inhibitor, DHMEQ, mimic ch128.1Av sensitization to CDDP? d) Is ch128.1Av-induced inhibition of Akt activity responsible, in part, for the sensitization of cancer cells to CDDP-induced apoptosis? Does the Akt chemical inhibitorLY294002 or Akt siRNA mimic ch128.1Av sensitization to CDDP? and e) Does the treatment of malignant B-cells with ch128.1Av involve mitochondrial signaling for apoptosis? The findings presented herein support the above hypothesis.

**Materials and methods**

**Reagents.** RPMI-1640, opti-MEM and fetal bovine serum (FBS) were purchased from Invitrogen (Carlsbad, CA, USA). LY294002 was purchased from Merck Japan (Tokyo, Japan). DHMEQ was a kind gift from Dr K. Umezawa (Keio University, Japan). Anti-Bcl_{2}, anti-clAP1, anti-PARP, anti-caspase 9, anti-survivin, anti-human phospho-Akt (Ser473), anti-Akt and anti-β-actin antibodies were obtained from Cell Signaling Technology (Beverly, MA, USA). Secondary HRP-conjugated anti-rabbit or anti-mouse IgG antibodies, Akt siRNA and control scramble siRNA were purchased from Sigma-Aldrich (St. Louis, MO, USA). Protein A-agarose was purchased from Pierce (Rockford, IL, USA). The Annexin V-FITC kit was purchased from Beckman Coulter (Marseille, France).

**Antibody-avidin fusion protein.** ch128.1Av has been described previously (12). Briefly, this molecule was expressed in the murine myeloma cell line Sp2/0-Ag14 and purified from culture supernatants by using affinity chromatography as described (12,17). Purity was assessed by Simply blue (Invitrogen) staining of SDS-PAGE gels. All protein concentrations were determined by the bicinchoninic acid based protein assay (BCA Protein Assay, Thermo Fisher Scientific, Rockford, IL, USA) and ELISA as described (17).

**Cell lines.** The human cell lines IM-9 (EBV-transformed B-lymphoblastoid cell line originally isolated from the blood of a patient with multiple myeloma) and RPMI-8226 (a multiple myeloma cell line also isolated from the blood of a patient with multiple myeloma) were obtained from Human Science Technology (Osaka, Japan). Cells were cultured at 37°C, 5% CO₂ in RPMI-1640 medium supplemented with 10% FBS, 1% NaHCO₃, and 1% penicillin, streptomycin (v/v).

**Measurement of mitochondrial membrane depolarization.** The mitochondria-specific dye 3,3-dihexyloxycarbocyanine (DiOC₆; Invitrogen) was used to measure the mitochondrial membrane potential in both cell lines before and after 24 h of treatment with ch128.1Av as previously reported (19).

**Western blotting.** IM-9 and 8226 cells (4x10⁵ cells/ml) were seeded in a 100-mm dish containing 9 ml of the complete medium. The cells were treated with indicated concentrations of ch128.1Av for 24 h, washed 2 times with PBS, and then treated with 10 μg/ml of CDDP for an additional 24 h. The cells were harvested in PBS on ice and centrifuged at 3,500 rpm for 5 min. The cells were lysed in 100 μl of lysis buffer (1% Triton X-100, 20 mM Tris, 137 mM NaCl, 1 mM PMSF, 2 mM Na₃VO₄, and 10 μg/ml leupeptin). The cell lysate was centrifuged at 15,000 g for 10 min, and the supernatant was used for further analysis. Protein concentrations were determined using the Coomassie Brilliant Blue Method. The proteins were denatured at 95°C for 5 min in loading buffer (60 mM Tris, 2.5% SDS, 10% glycerol, 5% 2-ME, and 0.01% bromophenol blue). Aliquots containing 70 μg of total protein from each sample were separated by SDS-PAGE and transferred onto a PVDF membrane at 200 mA for 1 h. After the transfer, the membrane was washed for 30 min at room temperature in a TBS-Tween buffer (20 mM Tris-HCl, pH 7.6, containing 137 mM NaCl and 0.1% Tween-20) supplemented with 5% non-fat milk. The membrane was washed three times with TBS-Tween and probed for 1 h with the primary antibody diluted at 1/300 with 5% non-fat milk in TBS-Tween. After the membrane had been washed 6 times with TBS-Tween, the membrane was incubated with a secondary HRP-conjugated anti-rabbit or anti-mouse IgG antibodies diluted at 1/3000 with 5% non-fat milk TBS-Tween for 1 h at room temperature. Finally, after the membrane had been washed with TBS-Tween eight times the proteins were visualized on X-ray film with an ECL Western blotting detection kit (Perkin Elmer Life Sciences, Tokyo, Japan).

**Transfection with siRNA.** Cells were cultured in 3 ml of OptiMEM medium supplemented with FBS. Transfections with
targeted siRNA (Sigma-Aldrich) or control scramble siRNA (Sigma-Aldrich) were performed using the Xtreme GENE reagent (Roche Diagnostics Corporation, Indianapolis, IN, USA), according to the manufacturer's instructions. To determine Akt siRNA-induced sensitization to CDDP-induced apoptosis following transfection, the cells were treated with CDDP for an additional 24 h, then were processed for the Annexin V/Propidium Iodide staining and analyzed by flow cytometry as described above.

Analysis of DNA binding activity. DNA binding activity was measured by using the TransAM™ Transcription Factor Assays kit (Active Motif, Tokyo, Japan) according to the manufacturer's instructions.

Statistical analysis. Assays were set up in triplicates and the results are expressed as the mean ± SD. Statistical analysis was performed using the Student's t-test.

Results

ch128.1Av-induced sensitization of malignant B-cell lines to apoptosis by CDDP. The malignant B-cell lines IM-9 and 8226 were used as model systems to investigate the effect of ch128.1Av on the response of cancer cells to chemotherapeutic drugs such as CDDP. The IM-9 and 8226 cell lines were treated with different concentrations of ch128.1Av for 24 h and followed by treatment with CDDP (10 μg/ml) for an additional 24 h. The cells were then examined for apoptosis. While treatment with ch128.1Av alone or CDDP alone resulted in no significant apoptosis, the combination treatment resulted in significant potentiation of apoptosis (Fig. 1). By comparison, the sensitization of the cell line 8226 was more potent than the sensitization of the IM-9 cell line. These findings demonstrate that ch128.1Av is able to modify the apoptotic pathway(s) in the cell lines by reducing the threshold of resistance so that CDDP treatment can trigger apoptosis. We then examined the potential underlying mechanism by which ch128.1Av signals the cells and results in chemosensitization.

Inhibition of the constitutively activated NF-κB pathway in malignant B-cells by ch128.1Av. The above findings of ch128.1Av-mediated sensitization to CDDP apoptosis may have resulted from the inhibition of anti-apoptotic gene products that are regulated by the NF-κB pathway. To test this hypothesis, the cancer cells were treated with various concentrations of ch128.1Av for 24 h and cell lysates were prepared for Western blot analysis. Treatment of IM-9 cells with ch128.1Av resulted in a significant inhibition of the activation of NF-κB as evidenced by the decrease in phospho-p65 at concentrations ≥16 nM ch128.1Av and complete inhibition of phosphorylation at 32 nM (Fig. 2A, left panel). There was no effect on total p65 protein level, suggesting that the effect of ch128.1Av occurs at the activation level and not at the expression level. β-actin was used as a loading control. For 8226 cells, there was significant decrease in the levels of phospho-p65 at ≥8 nM ch128.1Av and more inhibition at 32 nM (Fig. 2A, right panel). Like IM-9, there was no effect on total p65 protein levels.

The inhibition of the NF-κB pathway by ch128.1Av as shown above by Western blot analysis was also corroborated by using a DNA-binding assay for NF-κB. Clearly, a concentration of 16 nM was sufficient to significantly inhibit NF-κB DNA-binding activity in IM-9 and 8226 cells (Fig. 2B). The NF-κB inhibitor DHMEQ was used as an internal positive control. The role of NF-κB-induced sensitization to CDDP-induced apoptosis was further confirmed by the use of the NF-κB inhibitor DHMEQ. Treatment of IM-9 (Fig. 2C, left panel) and 8226 (Fig. 2C, right panel) cells with different concentrations of DHMEQ (10 and 20 μM) resulted in significant potentiation of sensitization to CDDP-induced apoptosis. Single agents alone had no effect. These findings show that blocking NF-κB activity can lead to sensitization to CDDP-induced apoptosis, suggesting that NF-κB-induced inhibition by ch128.1Av is involved in the chemosensitization of malignant B-cells to CDDP-induced apoptosis.

Inhibition of the constitutively activated Akt pathway in malignant B-cells by ch128.1Av. In addition to inhibition of the NF-κB pathway by ch128.1Av shown above, the constitutively
activated Akt pathway is also involved in the regulation of resistance to apoptosis as well as its crosstalk with the NF-κB pathway (20). We, therefore, hypothesized that ch128.1Av-induced inhibition of NF-κB may have resulted from inhibition of the Akt pathway. Treatment of IM-9 and 8226 with various concentrations of ch128.1Av resulted in significant decrease of phospho-Akt (ser 473) levels with no effect on the total Akt levels (Fig. 3A). In IM-9 (Fig. 3A, left panel), treatment with ≥8 nM ch128.1Av resulted in decreased phospho-Akt levels and there was complete inhibition at 32 nM. The concentration range of ch128.1Av in the inhibition of phospho-Akt was in the same range as observed in the inhibition of NF-κB seen in Fig. 2A. The effect of ch128.1Av on 8226 was less pronounced and the inhibition was observed at 32 nM of ch128.1Av (Fig. 3A, right panel). These results suggested that the inhibition of the Akt pathway by ch128.1Av may also be involved in the sensitization of malignant B-cell lines to CDDP apoptosis. To test this hypothesis, we used a specific inhibitor of the Akt pathway, namely, LY294002. Treatment of the cancer cells with various concentrations of LY294002 (10-50 μM) and followed by treatment with CDDP (1 and 5 μg/ml) resulted in significant enhancement of apoptosis. In IM-9 cells, treatment with 50 μM LY294002 in combination with CDDP (5 μg/ml) resulted in significant potentiation of apoptosis (Fig. 3B, left panel). Likewise, in 8226 cells, treatment with 50 μM of LY294002 resulted in significant enhancement of apoptosis in combination with CDDP (5 μg/ml) (Fig. 3B, right panel).
The direct role of Akt in the sensitization to CDDP-induced apoptosis was confirmed by the use of Akt siRNA. IM-9 and 8226 cells were treated with Akt siRNA or control siRNA for 24 and 48 h. Shown in Fig. 4A (left panel) treatment of IM-9 cells with Akt siRNA resulted in significant inhibition of Akt as determined by Western blotting. Likewise, treatment of
8226 with Akt siRNA also resulted in inhibition of Akt as shown in Fig. 4A, right panel. For sensitization to CDDP, IM-9 and 8226 cells were treated with Akt siRNA or control in the presence or absence of CDDP (10 μg/ml) and then examined for apoptosis. As seen in Fig. 4B treatment of IM-9 and 8226 with the combination of Akt siRNA and CDDP resulted in significant potentiation of apoptosis. These findings corroborate the findings observed above with the Akt inhibitor LY294002 that show that inhibition of the AKT pathway plays a role in CDDP-mediated cytotoxicity. These findings show that blockage of the Akt pathway can lead to chemosensitization and suggest that ch128.1Av-mediated inhibition of the Akt pathway, in addition to the NF-κB pathway, is also involved in the sensitization of malignant B-cells to CDDP-induced apoptosis.

Figure 5. ch128.1Av induces mitochondrial membrane potential depolarization in malignant B-cells. Mitochondrial membrane depolarization was assessed in IM-9 cells (A) and 8226 cells (B) using the DiOC6 dye by flow cytometry as described in Materials and methods. The cells were treated with various concentrations of ch128.1Av (0.02-2.5 nM) for 24 h and then examined for membrane potential. Values are expressed as Mean Fluorescence Intensity (MFI) of DiOC6 incorporation. Untreated cells are represented as 100 and treated cells are calculated as percentage of untreated cells. The data represent the mean ± SD of 3 independent experiments. p-value: medium control vs. treatment with 16 nM of ch128.1Av (Student's t-test).

Figure 6. ch128.1Av sensitizes malignant B-cells to apoptosis by CDDP via activation of the intrinsic apoptotic pathway. Total cell lysates derived from IM-9 cells (A) and 8226 cells (B) treated with various concentrations of ch128.1Av (0-32 nM) and CDDP (10 μg/ml) for 24 h were examined for levels of expression for Bcl-xL, cIAP-1, survivin, caspase-9 and PARP by Western analysis. β-actin served as an internal control for loading. The blots are representative of three independent experiments.

Potential underlying mechanism of ch128.1Av-mediated sensitization of malignant B-cells to apoptosis by CDDP. We have previously shown that a high concentration of ch128.1Av (50 nM) for treatment times of 48 h induces mitochondrial depolarization (13). Thus, we determined if the concentrations of ch128.1Av used in this study could also induce mitochondrial depolarization, which might play a role in its ability to sensitize cells to CDDP-mediated apoptosis. Cells were treated with various concentrations of ch128.1Av and examined for the mitochondrial membrane potential. Treatment with ch128.1Av resulted in significant mitochondrial membrane depolarization starting at concentrations of 0.02 nM in both IM-9 (Fig. 5A) and 8226 (Fig. 5B) cells. These findings suggest that the membrane depolarization by ch128.1Av may result in the downstream activation of the apoptosome and in combination with CDDP results in the potentiation of apoptosis.

In order to examine the effects mediated by ch128.1Av downstream of the mitochondrion and the NF-κB and Akt pathways, whole-cell lysates from cells treated with various concentrations of ch128.1Av alone or in combination with
CDDP were examined by immunoblotting for the expression levels of various proteins involved in these pathways. Treatment of IM-9 cells with ch128.1Av for 24 h resulted in the decrease of the anti-apoptotic gene products Bcl-xL, cIAP1 and survivin in the range of concentrations of 8-32 nM of ch128.1Av (Fig. 6A). There was also cleavage of caspase-9 but only at 32 nM of ch128.1Av and there was no cleavage of PARP with ch128.1Av alone. The cleavage of caspase-9 observed here is consistent with previous findings showing caspase-9 activity at concentrations above 10 nM in IM-9 cells treated for more than 48 h (15). In IM-9 cells, the combination treatment of ch128.1Av with CDDP (10 μg/ml) resulted in significant decrease in the expression levels of Bcl-xL, cIAP1, and survivin (Fig. 6A). The combination treatment also showed caspase-9 and PARP cleavage (Fig. 6A). In 8226 cells, treatment with ch128.1v alone also decreased the expression levels of Bcl-xL, cIAP1 and PARP, but not survivin (Fig. 6B). The combination treatment totally inhibited the expression of all of these gene products (Fig. 6B). Cleavage of caspase-9 and PARP were also increased by the combination treatment, consistent with apoptotic cell death. The downregulation of Bcl-xL and survivin by ch1281-induced inhibition of the Akt pathway was corroborated by treatment with siRNA Akt (Fig. 4A). These findings support our contention that the sensitizing ability of ch128.1Av is mediated, in part, by the inhibition of anti-apoptotic gene products regulated by the NF-xB and Akt pathways.

**Discussion**

This study provides evidence, for the first time, that treatment of malignant B-cells with ch128.1Av inhibits the constitutive NF-xB and Akt signaling pathways. This inhibition leads downstream to downregulation of anti-apoptotic gene products such as Bcl-xL and survivin and sensitized the cells to CDDP-induced apoptosis. The proposed model for the sensitization activity of ch128.1Av is shown in Fig. 7. The inhibition of NF-xB pathway was determined by decreased levels of phosphorylated p65. The inhibition of NF-xB activity and downregulation of anti-apoptotic gene products by ch128.1Av and chemosensitization was corroborated by the use of the NF-xB inhibitor DHMEQ, which mimicked ch128.1Av in the inhibition of NF-xB and chemosensitization to CDDP. Treatment of IM-9 and 8226 cells with ch128.1Av significantly inhibited the constitutive activity of the PI3K/Akt signaling pathway. Inhibition of this pathway resulted downstream in the inhibition of Bcl-xL and survivin and sensitized the cells to CDDP-induced apoptosis. The role of Akt pathway in ch128.1Av-induced sensitization of cancer cells to CDDP-induced apoptosis was corroborated by the use of both the PI-3K inhibitor LY294002 and by the use of siRNA for Akt. Treatment of IM-9 and 8226 cells with LY294002 or Akt siRNA inhibited the Akt pathway and both Bcl-xL and survivin expression and sensitized the cells to CDDP-induced apoptosis. The inhibition of Akt and NF-xB activities by ch128.1Av with the combination treatment with CDDP resulted in the activation of the mitochondrial apoptotic pathway and in the caspase-9, PARP cleavage and apoptosis. These findings establish the potential therapeutic implication of ch128.1Av alone or in combination with sub-toxic doses of chemotherapeutic drugs in drug-resistant malignant B-cells.

In mammals, the NF-xB contains five members: Rel-A (p65), Rel-B, c-Rel, NF-xB (p50 and its precursor p100) and NF-xB 2 (p52 and its precursor p100), the most abundant being the p65/p50 heterodimer (21). In normal cells, NF-xB activity is tightly controlled by IxB inhibitory proteins. NF-xB activation can be induced by a variety of stimuli resulting in the phosphorylation of IxB, ubiquitination and IxB degradation by the 26S proteasome, allowing the translocation of NF-xB to the nucleus and activation of gene transcription. NF-xB phosphorylation is catalyzed by the multi-protein IKK complex, which phosphorylates and activates the upstream NIK (21,22). Here, we show a significant decrease of the phosphorylation state of p65 at less than 8 h following treatment, suggesting of a novel function of ch128.1Av as a negative regulator of the NF-xB pathway.

NF-xB/Rel transcription factors bind to NF-xB control elements present in the promoter of a wide variety of target genes that regulate cellular differentiation, proliferation, survival and apoptosis (21,22). Activation of the NF-xB pathway is, in part, responsible for the transcriptional activation and expression of anti-apoptotic Bcl-2 family members which protect tumor cells from drug-induced apoptosis (21-23). In this study, we show that inhibition of the NF-xB pathway by ch128.1Av resulted in the down-regulation of Bcl-xL and survivin. We have reported that inhibition of Bcl-xL is critical for chemosensitization (23,24), and hence, our findings suggest that inhibition of Bcl-xL and survivin correlate with ch128.1Av-induced sensitization to CDDP.

Akt is involved in mediating various biological responses such as inhibition of apoptosis and stimulation of cell...
proliferation (20). Phosphorylation of Akt at serine or threonine residues activates the kinase activity of Akt. Activation of Akt can be mediated by various events, namely, binding of ligand to receptors on the cell membrane and causing autophosphorylation in the intracellular domain of the receptor. Thus, PI3k is recruited to the phosphotyrosine residues and becomes activated. In B-cells, PI3k is activated by BCR via SYK and BCAP (B-cell receptor associated protein). PI3k then phosphorylates membrane-bound PI2P to generate PI3P. The binding of PI3P to the PH domain anchors Akt to the plasma membrane and allows its phosphorylation and activation of PDK1. Also, Akt can be activated by cellular stress such as heat shock, UV, deschemia, hypoxia and oxidized stress (20).

The PI3K-Akt signaling pathway regulates many normal cellular processes and aberrant activation of the PI3K-Akt pathway has been widely implicated in many cancers (20). The PI3K-Akt pathway is a key regulator of cell survival through multiple downstream targets. IM-9 and 8226 cells exhibit constitutive activation of the Akt pathway. We have previously demonstrated that anti-CD20 monoclonal antibody, rituximab, inhibited the Akt pathway, leading to inhibition of Bcl-xL and ultimately to chemosensitization via the mechanism described above (23). Treatment of malignant B-cells with ch128.1Av resulted in decreased activation of the Akt pathway as well as depolarization of the mitochondrial membrane. However, little caspase-9 activation was observed (as expected) with ch128.1Av treatment alone due to the short treatment time of 24 h. Previous studies have shown activation of caspase-9 and -3 in cells treated with ch128.1Av for more than 48h (13, 15). Our results demonstrate that treatment of IM-9 and 8226 cells with ch128.1Av in combination with CDDP significantly suppressed expressions of Bcl-xL, survivin and cIAP1. Taken together, the combined treatment of ch128.1Av with CDDP resulted in enhanced cytotoxicity that was stronger and occurred faster compared to ch128.1Av alone treated cells. In addition, the combination treatment resulted in the activation of the mitochondrial apoptotic pathway.

Various mechanisms contribute to the Akt pathway in tumors including perturbation of upstream tensen, homolog deleted in chromosome 10 (PTEN) and phosphatidylinositol triphosphate (PIP3). Others include autocrine or paracrine stimulation of receptor tyrosine kinases and overexpression of growth factor receptors and/or RAS activation. Targeting of Akt directly or indirectly inhibits cell proliferation, promotes apoptosis and/or reverses sensitivity to chemotherapy (20). Cross-talk between the PI3K and the NF-κB pathways has been reported in a number of systems (25). Thus, the observed activation of the intrinsic apoptotic pathway results in enhanced apoptosis. Our data suggest that ch128.1Av can effectively break the tumor cell resistance to CDDP at very low concentrations and could thereby support the clinical applicability of a combination of ch128.1Av and CDDP in the treatment of B-cell malignancies.

Acknowledgements
This study was supported by NIH/NCI grants R01CA107023, K01CA138559, R01 supplements CA107023-02S1 and CA57152-13S1, and the NIH/NCI training grant T32-CA009120. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.

References


